Matinas Biopharma Holdings Inc. (MTNB)
$0.19
$-0.52
(-73.72%)
As on 11-Sep-2026 16:22EDT
Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.8
-
Debt to Equity
0
-
Book Value
$0.3
-
EPS
$-1.3
-
Face value
--
-
Shares outstanding
14,692,796
10 Years Aggregate
CFO
$-124.79 Mln
EBITDA
$-183.84 Mln
Net Profit
$-149.84 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Matinas Biopharma Holdings (MTNB)
| -68.4 | -- | -- | -88.6 | -71.7 | -66.1 | -42.6 |
|
BSE Sensex
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Matinas Biopharma Holdings (MTNB)
| 14.9 | -95.2 | -56.8 | -50.5 | -25.7 | -40.1 | 281.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Matinas Biopharma Holdings (MTNB)
|
0.2 | 3.0 | 0.0 | -7.3 | -- | -220.5 | -- | 1.5 |
| 82.9 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 263.5 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 73.8 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 56.1 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 107.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 347.0 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 534.5 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 587.5 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 334.6 | 9,822.5 | 0.0 | -339.1 | -- | -30.6 | -- | 7.4 |
Shareholding Pattern
View DetailsAbout Matinas Biopharma Holdings (MTNB)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid... nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey. Read more
-
Co-Founder, CEO, President & Director
Mr. Jerome D. Jabbour J.D.
-
Chief Financial Officer
Mr. Keith A. Kucinski CPA, M.B.A.
-
Headquarters
Bedminster, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Matinas Biopharma Holdings (MTNB)
What is the current share price of Matinas Biopharma Holdings Inc (MTNB) Today?
The share price of Matinas Biopharma Holdings Inc (MTNB) is $0.19 (NYSE) as of 11-Sep-2026 16:22 EDT. Matinas Biopharma Holdings Inc (MTNB) has given a return of -71.69% in the last 3 years.
What is the current PB & PE ratio of Matinas Biopharma Holdings Inc (MTNB)?
Since, TTM earnings of Matinas Biopharma Holdings Inc (MTNB) is negative, P/E ratio is not available.
The P/B ratio of Matinas Biopharma Holdings Inc (MTNB) is 1.50 times as on 11-Sep-2026, a 72 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.31 |
0.66 |
2024 |
-0.11 |
0.34 |
2023 |
-0.04 |
0.05 |
2022 |
-0.10 |
0.06 |
2021 |
-0.19 |
0.08 |
What is the 52 Week High and Low of Matinas Biopharma Holdings Inc (MTNB)?
The 52-week high and low of Matinas Biopharma Holdings Inc (MTNB) are Rs 2.14 and Rs 0.18 as of 13-Sep-2026.
What is the market cap of Matinas Biopharma Holdings Inc (MTNB)?
Matinas Biopharma Holdings Inc (MTNB) has a market capitalisation of $ 3 Mln as on 11-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Matinas Biopharma Holdings Inc (MTNB)?
Before investing in Matinas Biopharma Holdings Inc (MTNB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.